Pharmaceutical Executive: April 2023

Christi Shaw, this year’s Healthcare Businesswomen’s Association (HBA) Woman of the Year, stays true to her beliefs—and life mission—of helping others.

Marketing leaders discuss the powerful role life sciences companies can play in the expanding digital landscape for healthcare communications—as “one of the helpful voices” in driving the customer and patient conversations that matter most.

It’s time for pharma brands to recognize the potential of TikTok as a promotional platform and develop a strategy to not only stand out but make an impact.

After the pandemic forced fundamenta­l­­­­ changes in the ways pharma and key opinion leaders worked together, both groups are using what they learned for a more seamless connection.

What Smita Pillai, global chief diversity, equity, and inclusion (DE&I) officer, Regeneron, learned from two decades in DE&I roles.

Over two years into a bear market, it still can’t catch a sustainable bid.

Taking stock as the Orphan Drug Act hits its 40-year anniversary.

Shift focus in orphan and ultra-orphan messaging to clinical benefit.

The time is ripe to double down on local “market-fit” capabilities.

US pharma industry handcuffed by restrictions, group argues.

Regardless of engagement mode pursued, personalization is the key.

Click the title above for a link to open the Pharmaceutical Executive April 2023 issue in an interactive PDF format.